CellOPTIQ® offers significant advantages over other platforms

 

A broad range of reference and therapeutic compounds have been tested to demonstrate that CellOPTIQ®:

  • Is predictive of the clinical setting (correlates well with patient ECG)

  • Is predictive of in vivo models especially compounds with multi ion channel effects or effects on contractility

  • Offers significant advantages over other platforms

  • Provides very low false negative liability

 

Pharma Case Studies

Validation Experiments with Pharmaceutical Companies’ Compounds Demonstrate the Power of CellOPTIQ®

Case-1-Euro-Pharma-Assay-Comparison-2.png
Case-2-US-Pharma-Assay-Comparison.png
Case-3-Euro-Pharma-Assay-Comparison.png
Case-4-Euro-Pharma-Assay-Comparison.png
 

Modalities Comparison

Comparison of CellOPTIQ with Rabbit Wedge and Other Modalities Using 19 Reference Compounds

Modalities-Comparison.png

CellOPTIQ® outclasses many of the comparable platforms, especially in the identification of known reference compounds. CellOPTIQ® was the only platform without a false negative liability.

 
 

 

CellOPTIQ® Generates Data Which is Predictive of the Clinical Setting

 

Positive correlation observed between results of Axiogenesis hiPSC-CMs tested in vitro on CellOPTIQ® system and human EP treated with same range of Quinidine concentrations.

 
Graph showing voltage sensitive dye data from the CellOPTIQ platform